![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
Abstract
The aging global population continues to drive increasing demand for cosmaceuticals and cosmetic surgery among older men and women. Since the discovery in the 1990s that estrogen receptors are present in skin cells and decline in number from the onset of menopause in women, researchers have explored a number of ways in which estrogen can improve skin condition. Skin is estrogen responsive, and several studies now exist to support the antiaging properties of estrogen replacement therapies in postmenopausal women. Both systemic and topical estrogens appear to have positive effects on hormonal aging, increasing skin collagen content, thickness, elasticity and hydration. Estrogen therapies may also improve wound healing and reduce the incidence of wound complications. This review explores the potential for targeted estrogen replacement as a therapeutic option for long-term skin management in postmenopausal women.
Declaration of Interest: Disclosure of activities within the past 12 months:
Industry Consultations: Abbott Laboratories; Agile Therapeutics; Bayer Healthcare; CHEMO; Corcept; Endoceutics; Ferring Pharmaceuticals; Merck, previously Schering Plough, Organon; Shionogi; TEVA; Warner-Chilcott; Watson Pharmaceutical.
Industry Research Support for Research Activity: Abbott; Bayer Healthcare; Endoceutics; Pfizer; TEVA previously Duramed; Warner Chilcott; Watson Pharmaceutical.
Direct Industry Honoraria for Lecturing: Bayer Healthcare; Ferring Pharmaceuticals; Pfizer.
Pharmaceutical Stock Holdings: None.